PharmaShots | Incisive News in 3 Shots

Subscribe Now

FLT3 Mutation

Astellas' Xospata (gilteritinib) Receives NMPA's Conditional Approval for R/R AML with a FLT3 Mutation

Astellas' Xospata (gilteritinib) Receives NMPA's Conditional Approval for R/R AML with a FLT3 Mutation

February 4, 2021

Astellas Reports NMPA's Acceptance of NDA for XOSPATA (gilteritinib) to Treat R/R AML with a FLT3 Mutation in Adults

Astellas Reports NMPA's Acceptance of NDA for XOSPATA (gilteritinib) to Treat R/R AML with a FLT3 Mutation in Adults

April 10, 2020

$Astellas' Xospata (gilteritinib) Receives Health Canada Approval for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation$

Astellas' Xospata (gilteritinib) Receives Health Canada Approval for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mut...

January 15, 2020

$Astellas' Xospata (gilteritinib) Receives EC's Approval as Monotherapy for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation$

Astellas' Xospata (gilteritinib) Receives EC's Approval as Monotherapy for Relapsed or Refractory Acute Myeloid Leukemia with a FL...

October 25, 2019

Astellas to Launch Xospata (gilteritinib) for R/R Acute Myeloid Leukemia (AML) with FLT3 Mutation- in the US

Astellas to Launch Xospata (gilteritinib) for R/R Acute Myeloid Leukemia (AML) with FLT3 Mutation- in the US

December 12, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us